Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial

This phase II / III clinical trial was conducted to evaluate the immunogenicity and safety of the Tetravalent Influenza vaccine (Split virion) I.P. (TetIV) developed indigenously in the country for the first time by M/s Cadila Healthcare Limited, India containing two influenza A and two influenza B...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Shrikant, Singh, Veer Bahadur, Kumar, Sanjay, Prajapati, Vipul, Patel, Jitendra, Vukkala, Rajesh, Jangid, Sanjay Kumar, Sanmukhani, Jayesh, Gupta, Gaurav, Patel, Pradip, Mittal, Ravindra, Glueck, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037459/
https://www.ncbi.nlm.nih.gov/pubmed/29461913
http://dx.doi.org/10.1080/21645515.2018.1441654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037459/
https://www.ncbi.nlm.nih.gov/pubmed/29461913
http://dx.doi.org/10.1080/21645515.2018.1441654

Ejemplares similares